10x Genomics (NASDAQ:TXG) stock slid 14% Wednesday amid news that Illumina (ILMN) has acquired single cell analysis technology company Fluent BioSciences and a downgrade by Deutsche Bank.

Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...

Why ALZpath, GeneDX, 10x Genomics, Protagonist Therapeutics, and Recursion are among the most innovative biotech companies of 2025.

We offer a range of services, including single cell RNA sequencing and spatial transcriptomics. Our facility is equipped with state-of-art instruments, including the 10X Genomics Chromium X which ...

Oxford Nanopore Technologies announced its expanded collaboration with 10x Genomics, Inc. to enable seamless compatibility between their latest technologies, bringing more accurate, cost-effective and ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

Single-cell transcriptomics has revolutionized the ... particularly in droplet-based methods such as Drop-seq and 10x Chromium—frequently lead to inaccurate results, causing researchers to ...

"This development further validates the strength of our broad patent portfolio, which helps protect and preserve the world-class innovation engine at 10x," said Eric S. Whitaker, Chief Legal ...

The high level of single-cell resolution leads to groundbreaking insights across applications, including gene and protein expression investigation, immune phenotyping, CRISPR perturbation analysis, ...

The Single-Cell Analytics Innovation Lab (SAIL ... into an easy-to-use package to perform and develop droplet microfluidics experiment. Xenium by 10X Genomics In Situ platform enables subcellular ...